CareDx (CDNA) Stock Forecast & Price Target

CareDx is viewed favorably because its core transplant franchise is accelerating, with Q3'26 revenue of $139M, core transplant revenue of $107M, and transplant volumes near 61k, reflecting the fastest unit growth in four years alongside strong gross margins and positive EBITDA. The investment case is further strengthened by the removal of the Medicare LCD overhang, which preserved bundled HeartCare coverage and left for-cause testing intact, while management raised 2026 revenue guidance to $520M-$530M and EBITDA guidance to $90M-$100M. It also has a more attractive growth mix after selling lower-margin lab products for $170M and acquiring Naveris, which adds a faster-growing, higher-margin oncology MRD platform plus an AlloHeme pipeline that could expand the total addressable market.

CareDx is heavily dependent on AlloSure Kidney and AlloMap Heart, so any shortfall in reimbursement, volume, or clinician adoption would directly pressure its revenue base and weaken confidence in its core transplant diagnostics franchise. Its growth strategy also carries execution risk because launching additional diagnostic solutions requires substantial R&D, clinical validation, approvals, and time, while transplant testing technology is evolving rapidly and could leave the company behind. Slower adoption by clinicians and healthcare administrators, driven by liability concerns and reluctance to change historical practices, further limits uptake at transplant centers and reinforces a negative fundamental outlook.